RT Journal Article
SR Electronic
T1 Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19007963
DO 10.1101/19007963
A1 Maponga, Tongai G
A1 McNaughton, Anna L
A1 Van Schalkwyk, Marije
A1 Hugo, Susan
A1 Nwankwo, Chikezie
A1 Taljaard, Jantjie
A1 Mokaya, Jolynne
A1 Smith, David A
A1 van Vuuren, Cloete
A1 Goedhals, Dominique
A1 Gabriel, Shiraaz
A1 Andersson, Monique I
A1 Preiser, Wolfgang
A1 van Rensburg, Christo
A1 Matthews, Philippa C
YR 2019
UL http://medrxiv.org/content/early/2019/12/19/19007963.abstract
AB Objective Prompted by international targets for elimination of hepatitis B virus (HBV) infection, we performed a cross-sectional observational study of adults with chronic HBV (CHB) infection in South Africa, characterising individuals with HBV monoinfection vs. those coinfected with HBV/HIV, to evaluate the impact of therapy and to guide improvements in clinical care as guidelines for antiviral therapy change over time.Design We prospectively recruited 115 adults with CHB, over a period of one year at a university hospital in Cape Town, South Africa. HIV coinfection was present in 39 (34%) subjects. We recorded cross-sectional demographic, clinical and laboratory data.Results Adults with HBV monoinfection were comparable to those with HBV/HIV coinfection in terms of age, sex and body mass. HBeAg-positive status was more common among those with HIV coinfection (p=0.01). However, compared to HBV/HIV coinfection, HBV monoinfected patients were less likely to have had assessment with elastography (p<0.0001) and less likely to be on antiviral treatment (p<0.0001). The HBV monoinfected group was more likely to have detectable HBV viraemia (p=0.04), and features suggesting underlying liver disease including moderate/severe thrombocytopaenia (p=0.007), elevated bilirubin (p=0.004), and APRI score >2 (p=0.02). Three cases of hepatocellular carcinoma were documented, all in patients with HBV monoinfection.Conclusion In this setting, individuals with HBV monoinfection are disadvantaged in terms of clinical assessment and appropriate antiviral therapy compared to those with HIV coinfection, associated with relatively worse liver health. Enhanced advocacy, education, resources and infrastructure are required to optimise interventions for CHB.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Wellcome Trust (grant ref 110110).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll data referred to in the manuscript are available as supplementary files (links provided in manuscript). https://figshare.com/s/756eff7c317ef041cf0e